MCID: HDR002
MIFTS: 56

Hidradenitis Suppurativa

Categories: Genetic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hidradenitis Suppurativa

MalaCards integrated aliases for Hidradenitis Suppurativa:

Name: Hidradenitis Suppurativa 12 76 53 25 43 44 15 73
Acne Inversa 53 25 37 40
Hidradenitides, Suppurative 25
Suppurative Hidradenitides 25
Hidradenitis, Suppurative 25
Suppurative Hidradenitis 25
Acne Inversa, Familial 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2280
ICD10 33 L73.2
MeSH 44 D017497
NCIt 50 C128429
SNOMED-CT 68 59393003
KEGG 37 H00681
UMLS 73 C0162836

Summaries for Hidradenitis Suppurativa

NIH Rare Diseases : 53 Hidradenitis suppurativa (HS) is an inflammatory, chronic skin disease characterized by recurrent, painful, boil-like lumps (nodules) under the skin. HS affects the areas around skin folds (e.g., armpits, groin, and breasts) and where apocrine glands (a form of sweat gland) and hair follicles are found. It is not contagious. It typically manifests as a single pocket of pus (abscess) or hard, sebaceous lumps (lumps composed of sebum, or oil, which is excreted by the sebacous glands associated with hair follicles). It may progress to painful, deep-seated, inflamed clusters of lesions with chronic seepage involving significant scarring. In most cases, the cause of HS is unknown. It is likely that it results from a combination of genetic and environmental factors. Some cases of HS have been associated with specific genes, including NCSTN, PSEN1, and PSENEN.

MalaCards based summary : Hidradenitis Suppurativa, also known as acne inversa, is related to pyoderma and pyoderma gangrenosum, and has symptoms including pruritus and exanthema. An important gene associated with Hidradenitis Suppurativa is NCSTN (Nicastrin), and among its related pathways/superpathways are Wnt signaling pathway and Notch signaling pathway. The drugs Adalimumab and Anti-Inflammatory Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and neutrophil, and related phenotypes are craniofacial and hematopoietic system

Genetics Home Reference : 25 Hidradenitis suppurativa, also known as acne inversa, is a chronic skin disease characterized by recurrent boil-like lumps (nodules) under the skin. The nodules become inflamed and painful. They tend to break open (rupture), causing abscesses that drain fluid and pus. As the abscesses heal, they produce significant scarring of the skin.

MedlinePlus : 43 Hidradenitis suppurativa (HS) is a chronic skin disease. It can occur in one or multiple areas of your body. HS usually develops in your armpits, groin, and anal area. It causes long-term skin inflammation and can be painful. Symptoms include Blackheads and red, tender bumps, called abscesses. The abscesses get bigger, break open, and leak pus Tunnels that form under the skin between abscesses Scarring No one knows what causes HS. It is more common in women, African Americans, and people who have had acne. It usually starts after the teenage years. Treatments include antibiotics, anti-inflammatory medicines, and sometimes surgery. Losing weight or wearing looser clothing may help some patients avoid skin irritation.

Wikipedia : 76 Hidradenitis suppurativa (HS), also known as acne inversa, is a long term skin disease characterized by... more...

Related Diseases for Hidradenitis Suppurativa

Diseases related to Hidradenitis Suppurativa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 187)
# Related Disease Score Top Affiliating Genes
1 pyoderma 31.1 NOD2 TNF
2 pyoderma gangrenosum 31.1 NOD2 TNF
3 arthritis 30.7 IL17A NOD2 TNF
4 psoriasis 30.6 IL17A KRT10 KRT14 TNF
5 crohn's colitis 30.6 NOD2 TNF
6 dowling-degos disease 30.5 DSC2 KRT14 NCSTN PSENEN
7 colitis 30.4 IL17A NOD2 TNF
8 ulcerative colitis 30.4 IL17A NOD2 TNF
9 spondyloarthropathy 1 30.3 IL17A NOD2 TNF
10 spondylitis 30.3 IL17A NOD2 TNF
11 hidradenitis 30.3 DSC2 DSG2 IL12RB1 IL17A KRT10 KRT14
12 spondylarthropathy 30.3 NOD2 TNF
13 melkersson-rosenthal syndrome 30.2 NOD2 TNF
14 skin disease 30.2 IL17A KRT10 KRT14 TNF
15 perifolliculitis capitis abscedens et suffodiens, familial 11.7
16 acne inversa, familial, 1 11.7
17 papillon-lefevre syndrome 11.4
18 acne inversa, familial, 2, with or without dowling-degos disease 11.4
19 acne inversa, familial, 3 11.4
20 squamous cell carcinoma 10.8
21 neurofibromatosis, type ii 10.7
22 crohn's disease 10.7
23 inflammatory bowel disease 10.6
24 dowling-degos disease 1 10.5
25 malignant atrophic papulosis 10.5
26 down syndrome 10.4
27 amyloidosis 10.4
28 cellulitis 10.4
29 lymphedema 10.4
30 spondyloarthropathy 10.4
31 pustulosis of palm and sole 10.4
32 pyoderma gangrenosum-acne-suppurative hidradenitis syndrome 10.4
33 sapho syndrome 10.3
34 adenocarcinoma 10.3
35 elephantiasis 10.3
36 depression 10.3
37 familial mediterranean fever 10.2
38 langerhans cell histiocytosis 10.2
39 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 10.2
40 diabetes mellitus 10.2
41 mucinous adenocarcinoma 10.2
42 histiocytosis 10.2
43 arthropathy 10.2
44 folliculitis 10.2
45 interstitial keratitis 10.2
46 sebaceous gland disease 10.2 NCSTN PSENEN
47 miller fisher syndrome 10.2 PSENEN TNF
48 ileocolitis 10.2 NOD2 TNF
49 granulomatous dermatitis 10.2 NOD2 TNF
50 streptococcal meningitis 10.2 NOD2 TNF

Graphical network of the top 20 diseases related to Hidradenitis Suppurativa:



Diseases related to Hidradenitis Suppurativa

Symptoms & Phenotypes for Hidradenitis Suppurativa

UMLS symptoms related to Hidradenitis Suppurativa:


pruritus, exanthema

MGI Mouse Phenotypes related to Hidradenitis Suppurativa:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 9.55 IL17A KRT14 NCSTN PSEN1 TNF
2 hematopoietic system MP:0005397 9.5 IL12RB1 IL17A KRT14 NCSTN NOD2 PSEN1
3 immune system MP:0005387 9.17 IL12RB1 IL17A KRT14 NCSTN NOD2 PSEN1

Drugs & Therapeutics for Hidradenitis Suppurativa

Drugs for Hidradenitis Suppurativa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adalimumab Approved Phase 4,Phase 3,Phase 2 331731-18-1 16219006
2 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
3 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
4 Anesthetics Phase 4,Phase 1
5 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Anti-Bacterial Agents Phase 3,Phase 2,Not Applicable
7 Antibiotics, Antitubercular Phase 3,Not Applicable
8 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1,Early Phase 1
9 Immunoglobulins Phase 3,Phase 2,Phase 1,Early Phase 1
10 Antibodies Phase 3,Phase 2,Phase 1,Early Phase 1
11
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
12
Etanercept Approved, Investigational Phase 2 185243-69-0
13
Ustekinumab Approved, Investigational Phase 2 815610-63-0
14
Infliximab Approved Phase 2 170277-31-3
15
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
16
Ethinyl Estradiol Approved Phase 2 57-63-6 5991
17
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
18
Polyestradiol phosphate Approved Phase 2 28014-46-2
19
Drospirenone Approved Phase 2 67392-87-4 68873
20 Estradiol valerate Approved, Investigational, Vet_approved Phase 2 979-32-8
21 Immunosuppressive Agents Phase 2,Not Applicable
22 Anti-Infective Agents Phase 2,Phase 1,Not Applicable
23 Dermatologic Agents Phase 2,Not Applicable
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Not Applicable
25 Hormones Phase 2,Not Applicable
26 Hormone Antagonists Phase 2,Not Applicable
27 Angiogenesis Modulating Agents Phase 2
28 Peripheral Nervous System Agents Phase 2,Not Applicable
29 Analgesics Phase 2
30 Analgesics, Non-Narcotic Phase 2
31 Anti-Inflammatory Agents, Non-Steroidal Phase 2
32 Angiogenesis Inhibitors Phase 2
33 Interleukin 1 Receptor Antagonist Protein Phase 2
34 Complement System Proteins Phase 2
35 Gastrointestinal Agents Phase 2
36 Antiparasitic Agents Phase 1, Phase 2
37 Antimalarials Phase 1, Phase 2
38 Antiprotozoal Agents Phase 1, Phase 2
39 Contraceptives, Oral Phase 2
40 Diuretics, Potassium Sparing Phase 2
41 Estrogens Phase 2
42 Estradiol 3-benzoate Phase 2
43 Contraceptive Agents Phase 2
44 Mineralocorticoids Phase 2
45 Drospirenone and ethinyl estradiol combination Phase 2
46 diuretics Phase 2
47 Mineralocorticoid Receptor Antagonists Phase 2
48 Natriuretic Agents Phase 2
49 Estradiol 17 beta-cypionate Phase 2
50
Phenol Approved, Experimental Phase 1 108-95-2 996

Interventional clinical trials:

(show top 50) (show all 68)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Humira (Adalimumab) for Hidradenitis Suppurativa (HS) Peri-Surgically (SHARPS Study) Recruiting NCT02808975 Phase 4 Adalimumab;Placebo
2 Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS Not yet recruiting NCT03221621 Phase 4 Adalimumab Injection
3 Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa Completed NCT01468207 Phase 3
4 Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa Completed NCT01468233 Phase 3
5 Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa Completed NCT01635764 Phase 3
6 Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa Recruiting NCT02805595 Phase 3 23.4% Hypertonic saline;Saline
7 Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa Active, not recruiting NCT02904902 Phase 3 Adalimumab
8 Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) Not yet recruiting NCT03713632 Phase 3 Secukinumab;Placebo
9 This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). Not yet recruiting NCT03713619 Phase 3 secukinumab;placebo
10 To Determine the Efficacy of a Laser Device for the Treatment of Hidradenitis Suppurativa Terminated NCT00367328 Phase 3
11 Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients Completed NCT02421172 Phase 2
12 Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa Completed NCT02695212 Phase 2 Apremilast
13 To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT00827996 Phase 2 adalimumab
14 Anakinra as a Treatment for Hydradenitis Suppurativa Completed NCT01516749 Phase 2 anakinra
15 Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT03001622 Phase 2
16 Etanercept in Hidradenitis Suppurativa Completed NCT00329823 Phase 2 Etanercept sc 50mg per week for 12 weeks
17 Anakinra in Hidradenitis Suppurativa Completed NCT01558375 Phase 2 Water for injection;Anakinra
18 MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB Completed NCT02643654 Phase 2 MABp1;Placebo
19 A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa Completed NCT01704534 Phase 2 Ustekinumab
20 Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis Completed NCT03049267 Phase 2 Apremilast;Placebo Oral Tablet
21 Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa Completed NCT00918255 Phase 2 Placebo
22 Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa Completed NCT00795574 Phase 2 infliximab;Placebo Comparator
23 Etanercept for Treatment of Hidradenitis Completed NCT00107991 Phase 2 etanercept
24 A Study of Bermekimab in Patients With Hidradenitis Suppurativa Recruiting NCT03512275 Phase 2 Bermekimab Monoclonal Antibody 400 mg
25 A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) Recruiting NCT03628924 Phase 2 Guselkumab dose 1;Guselkumab dose 2;Guselkumab dose 3;Placebo
26 A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Recruiting NCT03607487 Phase 2 INCB054707;Placebo
27 A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Recruiting NCT03569371 Phase 2 INCB054707
28 Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Recruiting NCT03275870 Phase 1, Phase 2 Hydroxychloroquine
29 A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. Active, not recruiting NCT03248531 Phase 2 Bimekizumab;Adalimumab
30 Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) Active, not recruiting NCT03487276 Phase 2 IFX-1;Placebo
31 Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa Terminated NCT01838499 Phase 2
32 A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS Terminated NCT00722800 Phase 2 drospirenone and ethinyl estradiol (YAZ);Placebo
33 Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa Completed NCT00134134 Phase 1 efalizumab
34 Endoscopic Pilonidal Sinus Treatment With Additional Crystalized Phenol Completed NCT02277340 Phase 1
35 An Investigation Into the Efficacy of Provodine Topical Cream as Compared to 10% Benzoyl Peroxide Wash for the Treatment of Hidradenitis Suppurativa. Unknown status NCT01818167 Not Applicable 10% Benzoyl Peroxide Topical Body Wash;Provodine Topical Cream
36 Study to Compare Two Treatments for Axillary Hidradenitis Suppurativa: Carbon Dioxide Laser Versus Surgical Deroofing Unknown status NCT02163746 Not Applicable
37 Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa Unknown status NCT01063270 Not Applicable Clindamycin & Rifampin
38 Group Psychotherapy for Patients With Hidradenitis Suppurativa: Effects in Quality of Life Unknown status NCT02904408 Not Applicable
39 Patients With Hidradenitis vs Patients With Psoriasis: Psychological Impact Unknown status NCT02999698
40 Efficacy of Percutaneous Injection of Triamcinolone in the Treatment of Mammillary Fistula Unknown status NCT01315080
41 Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting Completed NCT02786576
42 Study on the Effect of NdYag Laser for the Treatment of Hidradenitis Suppurativa Completed NCT00494351 Not Applicable
43 A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa. Completed NCT02781818 Not Applicable Triamcinolone Acetonide 10mg/mL;Triamcinolone Acetonide 40mg/mL;Normal Saline
44 Association Between Hidradenitis Suppurativa and Spondyloarthritis Completed NCT03668925 Not Applicable
45 Pilot Study on Botulinum Toxin B as Treatment for Hidradenitis Suppurativa Completed NCT03103074 Not Applicable Botulinum B Toxin
46 Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients Completed NCT02739828
47 Activation of a Cutaneous Inflammasome in the Skin of Hidradenitis Suppurativa Patients Completed NCT02833909 Not Applicable
48 Quality of Life After Wide Surgical Excision in Patients With Hidradenitis Suppurativa Completed NCT02593604
49 A Small Clinical Study: Photodynamic Therapy to Treat Hidradenitis Suppurativa Completed NCT00395187 Not Applicable
50 Nutritional Status and Hidradenitis Suppurativa (Acne Inversa) Completed NCT03683238

Search NIH Clinical Center for Hidradenitis Suppurativa

Cochrane evidence based reviews: hidradenitis suppurativa

Genetic Tests for Hidradenitis Suppurativa

Anatomical Context for Hidradenitis Suppurativa

MalaCards organs/tissues related to Hidradenitis Suppurativa:

41
Skin, Breast, Neutrophil, Thyroid, Liver, Eye, Ovary

Publications for Hidradenitis Suppurativa

Articles related to Hidradenitis Suppurativa:

(show top 50) (show all 1376)
# Title Authors Year
1
Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial. ( 30482392 )
2019
2
Adolescent-Onset Hidradenitis Suppurativa: Prevalence, Risk Factors and Disease Features. ( 30368494 )
2019
3
Standardized Photographic Documentation of Hidradenitis Suppurativa/Acne Inversa. ( 30368496 )
2019
4
The in-hospital burden of hidradenitis suppurativa in patients with inflammatory bowel disease: a decade nationwide analysis from 2004 to 2014. ( 29431201 )
2018
5
Distinguishing Mild, Moderate, and Severe Hidradenitis Suppurativa. ( 29926079 )
2018
6
Incidence of Obstructive Sleep Apnea among Patients with Hidradenitis Suppurativa: a retrospective population-based cohort analysis. ( 29957857 )
2018
7
Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. ( 29380251 )
2018
8
The immunological disease continuum of inflammation against self as an explanation for the lack of association between hidradenitis suppurativa and autoimmune thyroid disease. ( 29327479 )
2018
9
Acne and hidradenitis suppurativa. ( 29380349 )
2018
10
Combined fractional carbon dioxide laser and long-pulsed neodymium : yttrium-aluminium-garnet (1064 nm) laser in treatment of hidradenitis suppurativa; a prospective randomized intra-individual controlled study. ( 29907956 )
2018
11
Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 2. ( 29363099 )
2018
12
Current and future treatment of hidradenitis suppurativa. ( 29981245 )
2018
13
Laser hair removal alters the disease course in mild hidradenitis suppurativa. ( 29933519 )
2018
14
Concurrent hidradenitis suppurativa and Dowling-Degos disease taken down a 'Notch'. ( 29441533 )
2018
15
Hidradenitis suppurativa is associated with polycystic ovary syndrome: a population-based analysis in the United States. ( 29378201 )
2018
16
Anti-TNFI+ therapy modulates mTORC1signalling in hidradenitis suppurativa. ( 29956847 )
2018
17
Acquired lymphangioma circumscriptum of the genitals in an individual with chronic hidradenitis suppurativa. ( 29387752 )
2018
18
Women with Hidradenitis Suppurativa Have an Elevated Risk of Suicide. ( 29959906 )
2018
19
Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy. ( 29130482 )
2018
20
Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 1. ( 29355905 )
2018
21
Surgical management of hidradenitis suppurativa: procedural trends and risk factors. ( 29936991 )
2018
22
Secondary gastrointestinal amyloid A amyloidosis possibly caused by hidradenitis suppurativa. ( 29933503 )
2018
23
Distinguishing Mild, Moderate, and Severe Hidradenitis Suppurativa. ( 29926084 )
2018
24
Radical resection and local coverage of hidradenitis suppurativa - acne inversa: analysis of results. ( 29924129 )
2018
25
Risk Factors for Hidradenitis Suppurativa in Patients with Inflammatory Bowel Disease. ( 29357084 )
2018
26
Blood parameters in a population of blood donors are not affected by hidradenitis suppurativa. ( 29952294 )
2018
27
Comment on "Hidradenitis suppurativa in children treated with finasteride-A case series". ( 29356110 )
2018
28
A case of pyoderma gangrenosum, acne, hidradenitis suppurativa (PASH) syndrome associated with diabetes mellitus type 1 treated with adalimumab. ( 29368847 )
2018
29
Patients affected by Dent disease 2 could be predisposed to hidradenitis suppurativa. ( 29430722 )
2018
30
A Novel Severity Assessment Scoring System for Hidradenitis Suppurativa. ( 29417136 )
2018
31
Squamous cell carcinoma of the perineum masquerading as necrotizing hidradenitis suppurativa. ( 29906008 )
2018
32
A case of Axillary Hidradenitis suppurativa treated with topical tacrolimus. ( 29368858 )
2018
33
Growing evidence for coronary artery disease risk factors in patients with severe hidradenitis suppurativa. ( 29357611 )
2018
34
Congenital nevus comedonicus complicated by a hidradenitis suppurativa-like lesion: Report of a childhood case. ( 29952017 )
2018
35
Reliability of the hidradenitis suppurativa clinical response (HiSCR) in the assessment of patients with hidradenitis suppurativa. ( 29959796 )
2018
36
The effect of oral clindamycin and rifampicin combination therapy in patients with hidradenitis suppurativa in Singapore. ( 29403298 )
2018
37
Hidradenitis Suppurativa in Kuala Lumpur, Malaysia: A 7-Year Retrospective Review. ( 29951091 )
2018
38
Prevalence of Type II Diabetes Mellitus Among Patients with Hidradenitis Suppurativa in the United States. ( 29339240 )
2018
39
Aggravation of mild axillary hidradenitis suppurativa by microwave ablation: results of a randomized intra-patient controlled trial. ( 29940205 )
2018
40
HIDRAdisk: an innovative visual tool to assess the burden of hidradenitis suppurativa. ( 29894009 )
2018
41
Drug-induced sarcoidosis in a patient treated with an interleukin-1 receptor antagonist for hidradenitis suppurativa. ( 29892670 )
2018
42
Hidradenitis suppurativa with SAPHO syndrome maintained effectively with adalimumab, methotrexate, and intralesional corticosteroid injections. ( 29922466 )
2018
43
Hidradenitis suppurativa in a patient with hyperandrogenism, insulin-resistance and acanthosis nigricans (HAIR-AN syndrome). ( 29991979 )
2018
44
Alexithymia affects patients with hidradenitis suppurativa. ( 30325328 )
2018
45
To what extent do disease severity and illness perceptions explain depression, anxiety and quality of life in hidradenitis suppurativa? ( 30171696 )
2018
46
Acute fatty liver of pregnancy in a woman with ulcerative colitis and familial hidradenitis suppurativa. ( 30214481 )
2018
47
Prevalence and Description of Hidradenitis Suppurativa in Down Syndrome: A Cross-sectional Study of 783 Subjects. ( 30460373 )
2018
48
Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis. ( 29689550 )
2018
49
Prevalence of hidradenitis suppurativa among patients with Down syndrome: a population-based cross-sectional analysis. ( 28662304 )
2018
50
Severe refractory hidradenitis suppurativa successfully treated with adalimumab in an HIV-positive/hepatitis C virus-positive patient. ( 30281563 )
2018

Variations for Hidradenitis Suppurativa

Expression for Hidradenitis Suppurativa

Search GEO for disease gene expression data for Hidradenitis Suppurativa.

Pathways for Hidradenitis Suppurativa

Pathways related to Hidradenitis Suppurativa according to KEGG:

37
# Name Kegg Source Accession
1 Wnt signaling pathway hsa04310
2 Notch signaling pathway hsa04330
3 Neurotrophin signaling pathway hsa04722

Pathways related to Hidradenitis Suppurativa according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.01 DSC2 DSG2 KRT10 KRT14 NCSTN PSENEN
2
Show member pathways
12.32 IL12RB1 IL17A NOD2 TNF
3
Show member pathways
12.19 DSC2 DSG2 KRT10 KRT14
4 11.98 NCSTN PSEN1 PSENEN
5
Show member pathways
11.94 NCSTN PSEN1 PSENEN
6 11.84 NCSTN PSEN1 PSENEN
7
Show member pathways
11.78 IL12RB1 IL17A TNF
8 11.54 IL12RB1 IL17A TNF
9
Show member pathways
11.4 NCSTN PSEN1 PSENEN
10 11.24 NCSTN PSEN1 PSENEN
11 11.06 IL17A TNF
12 10.99 NCSTN PSEN1 PSENEN
13 10.89 NOD2 TNF
14 10.49 NCSTN PSEN1 PSENEN
15 10.07 PSEN1 PSENEN
16 10.03 NCSTN PSEN1 PSENEN

GO Terms for Hidradenitis Suppurativa

Cellular components related to Hidradenitis Suppurativa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.56 DSG2 NOD2 PSEN1 TNF
2 desmosome GO:0030057 9.16 DSC2 DSG2
3 cornified envelope GO:0001533 9.13 DSC2 DSG2 KRT10
4 gamma-secretase complex GO:0070765 8.8 NCSTN PSEN1 PSENEN

Biological processes related to Hidradenitis Suppurativa according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 Notch signaling pathway GO:0007219 9.74 NCSTN PSEN1 PSENEN
2 keratinization GO:0031424 9.73 DSC2 DSG2 KRT10 KRT14
3 positive regulation of catalytic activity GO:0043085 9.69 NCSTN PSEN1 PSENEN
4 cornification GO:0070268 9.67 DSC2 DSG2 KRT10 KRT14
5 positive regulation of MAP kinase activity GO:0043406 9.65 NOD2 PSEN1 TNF
6 protein processing GO:0016485 9.63 NCSTN PSEN1 PSENEN
7 regulation of heart rate by cardiac conduction GO:0086091 9.61 DSC2 DSG2
8 positive regulation of interleukin-8 production GO:0032757 9.6 NOD2 TNF
9 regulation of synaptic transmission, glutamatergic GO:0051966 9.59 PSEN1 TNF
10 positive regulation of osteoclast differentiation GO:0045672 9.58 IL17A TNF
11 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.58 IL17A NOD2
12 membrane protein ectodomain proteolysis GO:0006509 9.58 NCSTN PSEN1 PSENEN
13 amyloid-beta metabolic process GO:0050435 9.56 NCSTN PSEN1
14 epithelial cell proliferation GO:0050673 9.55 NCSTN PSEN1
15 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.54 DSC2 DSG2
16 astrocyte activation GO:0048143 9.52 PSEN1 TNF
17 amyloid precursor protein metabolic process GO:0042982 9.5 NCSTN PSEN1 PSENEN
18 bundle of His cell-Purkinje myocyte adhesion involved in cell communication GO:0086073 9.49 DSC2 DSG2
19 Notch receptor processing GO:0007220 9.43 NCSTN PSEN1 PSENEN
20 amyloid precursor protein catabolic process GO:0042987 9.33 NCSTN PSEN1 PSENEN
21 Notch receptor processing, ligand-dependent GO:0035333 9.13 NCSTN PSEN1 PSENEN
22 amyloid-beta formation GO:0034205 8.8 NCSTN PSEN1 PSENEN

Molecular functions related to Hidradenitis Suppurativa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication GO:0086083 8.62 DSC2 DSG2

Sources for Hidradenitis Suppurativa

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....